Skip to content

Multicentrique Prospective Evaluation of Radiofrequency Surgical Treatment of Homorrhoidal Disease

Multicentrique Prospective Evaluation of Radiofrequency Surgical Treatment of Homorrhoidal Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04229784
Acronym
RF-GREP
Enrollment
150
Registered
2020-01-18
Start date
2019-07-01
Completion date
2021-07-31
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoids, Surgical Procedure, Unspecified

Keywords

hemorrhoids, radiofrequency surgery

Brief summary

Hemorrhoids consist of a tissue rich in blood vessels and are present in all individuals inside the anus. Hemorrhoidal disease (HD) is when hemorrhoids become troublesome and cause symptoms such as pain, bleeding, prolapse or seepage. The first steps in the treatment of HD involve either drugs or instrumental gestures (sclerosis, ligation). In the event of failure or of a disease that is significant from the outset, it is possible to envisage a surgical treatment. The use of a radiofrequency is a new technique, already used frequently by vascular surgeons in the treatment of varicose veins of the lower limbs. This technique has been developed for radiofrequency destruction of hemorrhoidal vascular tissue. In France, no studies have been carried out to evaluate this new technique.

Detailed description

Hemorrhoids consist of a tissue rich in blood vessels and are present in all individuals inside the anus (internal hemorrhoids). Hemorrhoidal disease (HD) is when hemorrhoids become troublesome and cause symptoms such as pain, bleeding, prolapse or seepage. The first steps in the treatment of HD involve either drugs or instrumental gestures (sclerosis, ligation). In the event of failure or of a disease that is significant from the outset, it is possible to envisage a surgical treatment. The use of a radiofrequency current (Rafaelo technique) in the treatment of hemorrhoidal disease is a new technique, already used frequently by vascular surgeons in the treatment of varicose veins of the lower limbs. This technique has been developed for radiofrequency destruction of hemorrhoidal vascular tissue. Although radiofrequency destruction of hemorrhoidal vascular tissue is already used in other European countries such as Poland, Germany, Belgium and Great Britain, there are very few studies on this minimally invasive surgical technique. This is particularly the case in France where no studies have been carried out to evaluate this new technique.

Interventions

PROCEDURERadiofrewuency surgery

The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue

Sponsors

Dr Abramowitz
CollaboratorUNKNOWN
Ramsay Générale de Santé
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male and female consultant for a grade II or III haemorrhoidal pathology after failure of medical-instrumental treatments. * Age \> 18 years old and \< 75 years old * Patient having signed an informed consent * Affiliate or beneficiary of a social security scheme * For patients taking anti-vitamin K (AVK) or oral anticoagulants (OACs) a short stop will be recommended according to HAS recommendations. * For patients on antiplatelet agents (APA), the relay and stopping procedures will be carried out according to the current recommendations of the HAS (26) * Patient eligible to be an outpatient

Exclusion criteria

* Patient with IBD (inflammatory bowel diseases) * Patient with haematological disease at risk of bleeding * Patient with anal fistulas * Patient unable to interrupt VKAs, OACs or APAs. * Patient with an associated anal fissure * External hemorrhoidal pathology * Patient participating in another clinical study * Pregnant or lactating women * Patient with pacemaker or implantable defibrillator * Protected patient: adult under guardianship, trusteeship or other legal protection, deprived of liberty by judicial or administrative decision

Design outcomes

Primary

MeasureTime frameDescription
HEMO-FISS-QoL3 monthsThe primary endpoint for assessing changes in the patient's quality of life will be the total score obtained on the HEMO-FISS-QoL Quality of Life Questionnaire at 3 months.

Countries

France

Contacts

Primary ContactMarie Barba
mh.barba@ecten.eu+330664888704
Backup ContactJean Francois OUDET
jf.oudet@ecten.eu+33683346567

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026